Classification models based on magnetic resonance imaging (MRI) may aid early diagnosis of frontotemporal dementia (FTD) but have only been applied in established FTD cases. Detection of FTD patients in earlier disease stages, such as presymptomatic mutation carriers, may further advance early diagnosis and treatment. In this study, we aim to distinguish presymptomatic FTD mutation carriers from controls on an individual level using multimodal MRI-based classification.
Frontotemporal lobar degeneration is a common cause of early-onset dementia with a similar prevalence to Alzheimer's disease in the presenile population [1] [2] [3] [4] [5] .
Although there are clinical disease criteria for the different clinical variants of frontotemporal dementia (FTD) [5, 6] , diagnosis is often complicated and delayed by clinical heterogeneity. This hinders clinicians in providing accurate prognosis, effective disease management and developing new treatments [7] [8] [9] [10] .
Multimodal magnetic resonance imaging (MRI) has been suggested as a promising biomarker to improve on diagnostic standards in FTD. In FTD patients, MRI revealed specific patterns of neurodegeneration, involving grey matter (GM) and white matter (WM) atrophy [11, 12, 21, 22, [13] [14] [15] [16] [17] [18] [19] [20] , differences in diffusion tensor imaging (DTI) measures [18, [22] [23] [24] [25] [26] [27] [28] , and differences in functional connectivity [29] [30] [31] [32] [33] [34] .
These patterns have subsequently been utilised on an individual level to create MRI-based classification algorithms that can discriminate between FTD patients and control subjects [26, [35] [36] [37] [38] [39] [40] [41] . Accurate classification of FTD patients using MRI measures is an important step towards a more substantiated diagnostic standard.
However, most classification models are based on established FTD cases, limiting generalisability in patients who are at an earlier disease stage. Still, detection of
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In order to characterise FTD pathophysiology at an earlier stage, presymptomatic carriers of autosomal dominant FTD gene mutations were compared to controls in MRI group analyses [43, 44, 53, [45] [46] [47] [48] [49] [50] [51] [52] . Carriers of the three most common FTD gene mutations microtubule-associated protein Tau (MAPT), progranulin (GRN),
and chromosome 9 open reading frame 72 (C9orf72) show brain alterations on MRI, even well before symptom onset. In these subjects, WM diffusivity changes [43, 48, 52] and functional connectivity changes [44, 45, 47, 48] are often, but not exclusively [50] [51] [52] , found in the absence of GM atrophy, suggesting that changes in the functional architecture and WM tracts may precede structural deterioration in the GM [46] . Nonetheless, multi-centre analyses of a large international cohort show GM loss in MAPT, GRN and C9orf72 carriers even before conversion [49, 53] .
Although these presymptomatic group differences give insight into the pathophysiological mechanisms of FTD, individual heterogeneity complicates its utility in FTD diagnosis. Therefore, translation from group differences to singlesubject classification models is imperative.
The present study brings two research areas together: we combine machine learning with presymptomatic FTD mutation carriers to study individual classification of FTD-pathology at an early stage. Our aim is to distinguish
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Methods
Design
In order to distinguish presymptomatic FTD mutation carriers from controls, we applied two models. First, we applied a recent behavioural variant FTD (bvFTD)control classification model [41] to our MRI data to investigate whether the model separates presymptomatic mutation carriers from controls. We shall refer to this model as the "bvFTD model". In a second analysis, we trained a new classification model on the presymptomatic mutation carriers and controls' data, which we evaluated using cross-validation. We shall refer to this model as the "carrier-control model". MRI pre-processing, feature selection and classification were performed identically to previous work [41] .
Participants
This retrospective study partially included previously published [48, 52, 54] [5, 6] or amyotrophic lateral sclerosis [55] criteria. Healthy controls were assumed to have equal FTD risk as the general population. For a more detailed description of the recruitment protocol, see earlier work [48, 52, 54] .
Inclusion criteria for the current study were: age between 40 and 70 years, and availability of a T1-weighted 3-dimensional MRI (3DT1w) scan, a diffusion-weighted imaging (DWI) dataset, and a resting-state fMRI T2*-weighted (rs-fMRI) scan.
Exclusion criteria were: current or past neurologic or psychiatric disorders, history of drug abuse, large image artefacts, and gross brain pathology other than
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MRI data acquisition
All subjects were scanned at the Leiden University Medical Centre using a 3T MRI scanner (Achieva, Philips Medical Systems, Best, The Netherlands) with an 8channel SENSE head coil. The imaging protocol included a whole-brain nearisotropic 3DT1w sequence for cortical and subcortical tissue-type segmentation, a DWI sequence for assessments of white matter integrity, and a rs-fMRI for the calculation of functional connectivity measures. Participants were instructed to lie still with their eyes closed and not to fall asleep during rs-fMRI. For scan parameters, see Table 1 . Pre-processing for DTI datasets included correction of motion and eddy-current induced distortion (eddy correct [61] ), calculation of voxel-wise measures of fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AxD, largest eigenvalue), and radial diffusivity (RD, average of the two remaining eigenvalues, DTIFIT [62] ). A global mean FA image was created by nonlinearly registering FA maps to the FMRIB58_FA template, and tract-based spatial statistics (FSL TBSS [63] ) was used to extract FA, MD, AxD and RD values using the standard FSL TBSS skeleton. The skeleton was thresholded at 0.2 to ensure skeleton extracted values originate from WM.
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For rs-fMRI data, pre-processing included motion correction [64] , brain extraction, spatial smoothing using a Gaussian kernel with a full width at half maximum of 3mm, grand mean intensity normalisation, motion artefact removal, and highpass temporal filtering (cut-off frequency = 0.01 Hz). Motion artefacts were removed using a single-session independent component analysis (ICA) to decompose the rs-fMRI data into distinct statistically independent components.
Subsequently, motion-related components were automatically identified and removed using the ICA-based automatic removal of motion artefacts (ICA-AROMA, version 0.3-beta) procedure [65] . Registration to standard space was performed in two steps. First, a temporal mean image calculated from the 4D rs-fMRI volume was registered to the 3DT1w image using Boundary-Based Registration [66] . Next, resulting registration parameters were concatenated to the 3DT 1 w-to-MNI152 template registration parameters to obtain the final registration parameters.
All registration and segmentation steps were critically reviewed and errors were corrected accordingly.
Feature selection
Cortical GM density (GMD) and WM density (WMD) were calculated as a weighted average of their respective regional WM or GM probability (SPM segmentation) weighted by the probability of a voxel being part of that specific
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14 tract or region. The latter probabilities were derived from the 48 Harvard -Oxford probabilistic anatomical brain atlas cortical regions (split into left and right) and from the Johns-Hopkins University white-matter tractography atlas for 20 WM tract regions. Voxels with region probability values less than 25% were excluded.
This provided a measure of brain atrophy of a specific GM region or WM tract. 
BvFTD model
For our first analysis, a bvFTD patient-control classification model [41] was applied to each subject's extracted feature vector. We applied the best performing, multimodal model that discriminated bvFTD patients from controls, which included the features FA, GMD, and FCor [41] , as well as age and gender.
Each subject's feature vector was fed into the model, resulting in a probability score from 0 to 1, where 0 represents a control subject and 1 represents a bvFTD patient. Extrapolated to our subjects, these scores showed how alike our presymptomatic FTD mutation carriers and healthy controls are to bvFTD patients.
Carrier-control model
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For the second analysis, feature vectors were used to train a logistic elastic net regression algorithm [41, [70] [71] [72] . The elastic net regression procedure estimates a sparse regression model that includes only a subset of the provided features by imposing a penalty for including features and for the weight of each feature. This way, elastic net provides a solution for the imbalance between the large number of features and the small number of subjects. Age and gender were included into the model without penalty to ensure that estimated feature regression coefficients were conditional on subject age and gender. Here, a probability score of 0 represented a control subject and 1 represented a presymptomatic FTD mutation carrier.
Cross-validation
Similarly to previous work [41, 72] , we trained our carrier-control model in a nested 10-fold cross-validation scheme to reduce classification bias. One part of the data (e.g. 10%) was set apart as a test set and served to test the gener alised classification performance of the elastic net regression model. The remaining parts (90%) were used to train the model. However, in addition to the classification performance, we also wanted to determine the optimal penalty size without overestimating classification performance [73, 74] . To this end, we used a second, nested 10-fold cross-validation loop on the training set over a grid of hyperparameters to determine the optimal penalty. In the nested loop, we estimated the model's hyperparameters that corresponded with the lowest
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17 binomial deviance, a goodness-of-fit measure that evaluates the difference between the predicted and actual observations. Next, these hyperparameters and corresponding penalties were used to train a model using the training set of the outer loop. Finally, the classification performance was tested on the test set of the outer loop. This process was repeated ten times to make sure that each subject was part of the test set at least once. Since the test set of the outer loop was neither used for model training, nor for parameter optimisation, potential prediction bias was reduced as much as possible [74] . The entire classification procedure was repeated 50 times to average classification outcome variability resulting from random partitioning in training and test folds. All classification analyses and evaluations were implemented in R version 3.3.2 (R core 2010, GLMnet package [71] ).
Classification performance
For both analyses, we quantified classification performances using receiver operating characteristic (ROC) curves. ROC curves were calculated by shifting the threshold for classifying an individual as patient (bvFTD model analysis) or carrier (carrier-control model analysis) from 0 to 1, and plotting the true positive rate (sensitivity) versus the false positivity (1 -specificity) for each intermediate point.
The area under this ROC curve (AUC) is a measure of classification performance insensitive to the distribution between the groups [75] . Additionally, we calculated the optimal operating point on the curve to calculate the model's sensitivity,
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18 specificity and classification accuracy, given equal class distribution and equal penalty for false positive and false negative predictions. For the carrier-control model analysis, we averaged AUC, accuracy, sensitivity and specificity values from the 50 times repeated nested cross-validations.
Multimodal classification
To obtain the best multimodal carrier-control model using several feature vectors, we performed step-wise feature concatenation as previously described [41, 72] .
First, we assessed classification performance for each feature separately.
Subsequently, we added a new feature to the best performing feature combination (i.e. highest AUC) of the previous step until all features were included in the model. The best performing feature combination will be referred to as the multimodal carrier-control model.
Statistical analysis
Statistical analyses of non-imaging data were performed using R (R Core 2016, Vienna, Austria). We tested for carrier-control differences using unpaired t-tests 
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19 against chance level, we used permutation tests (N = 5.000) [76] . In order to correct for multiple comparisons, we took the maximum AUC difference of the family of tests for each permutation. Then we compared the observed AUC difference to the new distribution of maximum AUC differences to get a familywise error rate corrected p-value. The alpha level required for statistical significance was set at p < 0.05.
Results
Demographics
In total, 103 subjects met the inclusion criteria ( Table 2) . Mean age was similar for mutation carriers (52.0 ± 8.6 years) and healthy controls (54.2 ± 7.5 years).
The proportion of female participants between mutation carriers (67%) and healthy controls (58%) was not different (p = 0.3). Education level was similar between groups (mutation carriers, 13.6 ± 2.9 years; healthy controls, 13.2 ± 2.4 years). MMSE was similarly distributed between groups (median [min-max], mutation carriers: 30 [24] [25] [26] [27] [28] [29] [30] , healthy controls: 29 [24] [25] [26] [27] [28] [29] [30] ). 
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BvFTD model
Application of the bvFTD model resulted in low bvFTD probability scores for most subjects (Figure 1A) , and the bvFTD probability scores were not significantly different in presymptomatic carriers (median = 0.015) than controls (median = 0.005, p = 0.22). ROC analysis of the bvFTD probabilities resulted in an AUC of 0.570, which was not significantly better than chance level (p = 0.11). Separated by gene (Figure 1B) , there were no differences between the four groups' bvFTD probability scores (p = 0. 
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22 defined by carrier status (Figure 1A) and genetic status (Figure 1B) . Probability scores were not significantly different for carriers and controls (p = 0.22), and did not differ between the four genetic groups (p = 0.60). Probability score results of the bvFTD patients and controls on which the bvFTD model was cross-validated were added for reference (Figure 1C, data 
Carrier-control model
The best performing unimodal carrier-control models included RD, WMD and MD, with AUCs of 0.646, 0.616, and 0.608, respectively. Of these models, only the RD model outperformed chance after family-wise error rate correction (p = 0.021, Table 3 ).
Step-wise concatenation resulted in the best performing multimodal model, which included the features RD and WMD, and outperformed chance with an AUC of 0.680 (p = 0.005). Classification performance did not improve when additional features were added to this model ( Table 4) . Interestingly, all models that outperformed chance level included RD, and most included several white matter features, such as WMD and the diffusivity features (i.e. FA, MD, AxD and/or RD). 
Table 4 | Multimodal classification performance
Step: ddd combined with: 
RD
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Application of the best performing multimodal carrier-control model resulted in carrier probability scores (Figure 2) , which were different between carriers (median = 0.629) and controls (median = 0.453, p = 0.001, Figure 2A ).
Furthermore, there was a difference between the four groups' carrier probability scores (p = 0.006) when separated by gene (Figure 2B) . Post-hoc tests revealed that GRN carriers had higher carrier probability scores than controls (Bonferroni family-wise error rate corrected p = 0.009). The other groups did not differ from each other.
Figure 2 | Classification results carrier-control model
Box and scatter plot of each subject's carrier probability score on a scale from 0 (representing control) to 1 (representing presymptomatic FTD mutation carrier) after application of the best performing carrier-control model including the features RD and WMD. Carriers had significantly higher scores than controls (Figure 2A , p = 0.001). Furthermore, there was an omnibus difference between the four genetic groups (Figure 2B , p = 0.006), and post-hoc tests revealed higher scores for GRN carriers than for controls (p = 0.009). Abbreviations: C9orf72 In an effort to improve on the FTD diagnostic criteria, single -subject classification using MRI measures has recently received significant attention [22, 26, [35] [36] [37] [38] [39] [40] [41] . A recent multimodal classification study incorporated structural, DTI and arterial spin labelling data to classify FTD (behavioural and language variants) from cognitively normal controls, and achieved an AUC of 0.96 [40] . Another
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27 classification study included tissue density, DTI and rs-fMRI measures, and achieved an AUC of 0.924 for bvFTD versus cognitively normal controls [41] .
These high classification performances are promising, but they are based on established FTD cases. It is unclear how FTD patient models generalise to earlier FTD stages, where brain alterations are less distinct . To test this, we applied a bvFTD model [41] on FTD mutation carriers in a presymptomatic stage. We hypothesised that if the bvFTD model would be able to recognise early-stage FTD pathology, our presymptomatic FTD mutation carriers would have higher probability scores than controls. We found that it was not possible to separate carriers from controls significantly better than chance using this model, as most carriers and controls had very low bvFTD probability scores. This could indicate that presymptomatic differences present in FTD mutation carriers are too subtle to be picked up by a classification model that was trained established bvFTD patients. However, it could also mean that most of our mutation carriers were still too far from conversion to have significant FTD-related changes. Since the bvFTD model was trained on patients, it stands to reason that classification of carriers and controls becomes more accurate as mutation carriers approach conversion.
Vice versa, one might expect the carriers with high probability scores to be closer to symptom-onset than carriers with lower probabilities. Although it was not statistically significant, there was a trend towards older age in carriers with a bvFTD probability score higher than 0.25 than in the rest of the carrier group (data not shown). It can therefore not be entirely ruled out that age is partly
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28 associated with a higher bvFTD score. Longitudinal research is warranted to formally test whether this model captures presymptomatic FTD-related changes as mutation carriers approach conversion.
By training classifiers on presymptomatic FTD mutation carriers and controls, we obtained a unimodal carrier-control model based on the RD feature and several multimodal carrier-control models that significantly outperformed chance level.
This suggests that classification models should be trained using early-stage FTD patients or presymptomatic FTD mutation carriers instead of advanced FTD cases, in order to be sensitive to early-stage FTD pathology. Furthermore, our carriercontrol models demonstrate that MRI-based machine learning is powerful enough to detect subtle pathological changes associated with FTD even before symptom-onset and on a single-subject level. Although classification performance beyond chance level is an important finding, it must be noted that AUCs of 0.646 and 0.680 are modest and far from sufficient for diagnostic use in the clinic. This is at least partly explained by our heterogeneous sample, as we included carriers of several genes in order to obtain sufficient sample size for robust crossvalidation. Heterogeneity further arose from the uncertain time to onset in our sample. Investigating a uniform population a few years before symptom-onset might lead to higher classification performance, but these data were not available to us.
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in the WM [46, [77] [78] [79] . Our results support this hypothesis, as the only unimodal model that outperformed chance was based on the RD feature, which was furthermore included in all multimodal models that significantly outperformed chance. Additionally, the majority of models that outperformed chance were based on WMD and DTI features. This means that our carrier-control model was able to combine subtle WM differences from the diffusion-weighted scans and the structural 3DT1w scan to classify a subject as mutation carrier or healthy control.
In addition to the uncertain time-to-onset, there were several other limitations.
Firstly, the bvFTD model was trained on a relatively small sample of 23 bvFTD patients and 35 controls. A model based on a larger sample might capture the heterogeneity of bvFTD pathology more completely, which could benefit generalisation to our presymptomatic sample. Furthermore, the model was trained on sporadic bvFTD patients, while it was applied to carriers of MAPT, GRN and C9orf72 genes. Since correlations between genetics, pathology and phenotype are not fully elucidated [80] , care must be taken not to over interpret our results. Specifically, pathological changes associated with non-behavioural variants [4] may be insufficiently recognised by the bvFTD model. Lastly, we used nested cross-validation to estimate out-of-sample performance for the carriercontrol model, which minimises prediction bias [74] . Still, measuring performance
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T
30 on a separate validation cohort would further increase the validity of this study.
Conclusion
Our data show that presymptomatic FTD mutation carriers can be distinguished 
